cyrilzakka/clinical-trials huggingface dataset:
Comparison Between Two Methods in the Acceleration of the Retraction of Upper Canines

Patients at the Orthodontic Department of University of Damascus Dental School will be examined and subjects who meet the inclusion criteria will be included.

Then, initial diagnostic records (diagnostic gypsum models, internal and external oral photographs, as well as radiographic images) will be studied to ensure that the selection criteria are accurately matched.

The aim of this study is to compare flapless bone cutting by mechanical drills to evaluate the acceleration of the retraction of upper canines versus traditional bone cutting by piezo-surgery in comparison with a control group without bone cutting after extraction of upper first premolars in class II type I patients.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18-27 years
* Patients who have malocclusion class II type I and who require first-premolar extraction with:
* Dentoalveolar class II type I with ANB between 5 and 9 degrees.
* Protrusion between (5-10 mm)
* Overbite between (0-4)
* Vertical dimension is normal or over the normal range
* Mild to moderate crowding
* All patients should have complete permanent occlusion on the maxilla
* All patients should have normal periodontal tissue and good oral health, which will be assessed by:

  1. Depth of the gingival pocket does not exceed 4 mm
  2. Plaque index does not exceed 1
  3. Gingival index does not exceed 1

Exclusion Criteria:

* Patients in which oral surgery under local anesthesia is contraindicated due to medical, psychological, or social reasons.
* Patients who have a general health problem that affects dental movement
* Patients who have undergone previous orthodontic treatment
* Patients with mixed occlusion
* Patients who have lost one or more of their teeth since birth or who have one of the permanent teeth extracted (except the third molar)
* Patients who have bad oral health or active periodontal disease
Phase 2, Multiple Ascending Dose Proof of Concept Study

This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.

This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels in hepatitis B virus(HBV) infected subjects.

Eligibility Criteria:
Inclusion Criteria:

* Capable of giving written informed consent.
* Capable of completing study requirements.
* Chronic hepatitis B positive.
* HBV treatment naïve.

Exclusion Criteria:

* Positive result for HCV(hepatitis C virus), HDV(hepatitis D virus) or HIV(human immunodeficiency virus).
* History or medical condition that could impact patient safety.
* Current or past abuse of alcohol or illicit drugs.
* Abnormal laboratory value or ECG.
* Pregnant or breastfeeding.
* Clinical, histologic or laboratory evidence of significant liver fibrosis or cirrhosis.
* Systemic immunosuppression.
* Received an investigational drug or investigational vaccine within the 90 days prior to the first dose of study drug.
Application of Monitoring and Intervention Technologies in Suboptimal Health Status

The purpose of this study is to use monitoring and intervention technologies in suboptimal health status in a general population in China and evaluate the effectiveness of these technologies in the improvement of suboptimal health status.

The Suboptimal health status questionnaire (SHSQ-25) is used to evaluate the suboptimal health status. The SHSQ-25 includes 25 questions. The score of the SHSQ-25 is from 0 to 100. Suboptimal health status is defined as the SHSQ-25 score above than 35. The higher scores of the SHSQ-25 one gets, the more severity of suboptimal health status he/she has. All participants are asked to fill in the SHSQ-25 before and after the intervention. If the score decreases after the intervention, it means that the suboptimal health status has been improved.

A monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology. Intervention technologies include a health information push technology and a field-effect meridian therapy instrument.

Eligibility Criteria:
Inclusion Criteria:

1. age between 18 and 60 years.
2. written informed consent.

Exclusion Criteria:

1. history of system diseases, such as cardiovascular diseases, digestive system diseases, diseases of respiratory system, blood and immune system diseases, nervous system diseases, endocrine system diseases, and diseases of the genitourinary system.
2. history of mental illness.
3. pregnant or breastfeeding.
4. use of antihypertensive, antidiabetic, or lipid-lowering drugs within the past two weeks.
5. participation in another trial.
6. unable to promise to not use drugs and other fish oils during the study.
7. unable to provide informed written consent.
CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19)

The coronavirus (COVID-19) pandemic has brought severe challenges for myeloma patients. Myeloma patients are considered ultra-high risk for COVID-19 and fall into the strictest group for shielding. When on treatment, but also during times of active surveillance, patients have to regularly and frequently leave shielding and visit the hospital for blood tests to monitor their disese. This is specifically for quantification of circulating tumour protein biomarker tests for paraprotein (PP) and/or serum free light chains (sFLCs) by specialised biochemistry units.

This research aims to evaluate the potential use of an at-home patient administered technique to sample blood. The purpose of the blood sampling technique is to monitor your disease status. We want to test if it is possible to monitor a patient's disease status using this alternative blood collection method when compared to monitoring disease status using the traditional blood collection methods (venous blood sampling).

The new VAMS method is not intended to be used interchangeably or will not replace the current method. This study is to evaluate an alternative sample type that may be used to improve the patient pathway, especially during these uncertain times.


Eligibility Criteria:
Inclusion Criteria:

1. A diagnosis of a B-cell dyscrasia
2. Measurable disease by serum free light chain assay
3. Signed informed consent

Exclusion Criteria:

1. Patients \<21 years of age
2. Cognitive impairment
3. Non-B Cell Dyscrasia patients
A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of Ensartinib Capsules.

The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers. In addition, the safety of Ensartinib Capsules in Chinese Healthy Volunteers who with High-fat meal or fasting state will also be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* age: 20 - 45 years;
* sex: male and female;
* body weight: Male ≥ 50 kg,female ≥ 45 kg, body mass index BMI (weight (kg)/height 2 (m2)) between 19-26 kg/m2 (including border);
* Healthy as judged by the investigator/subinvestigator based on the results of physical examinations and all lab tests;
* written informed consent;

Exclusion Criteria:

* Received any investigational drugs within 14 days before the screening test;
* Donated 200 mL of whole blood within 30 days before the screening test,or Donated 200 mL of whole blood during the study or within 30 days after completion of the study;
* Females who are lactating, pregnant, potentially child-bearing, or willing to get pregnant during the study period;
* History of drug or food allergies;
* Abnormal blood pressure or pulse，Abnormal laboratory tests;
* Participated in other clinical trials within 3 months before screening;
* Smoking and drinking within 3 months before screening or test results of smoke, alcohol, and drug abuse are positive;Positive for HBsAg, Hepatitis C virus (HCV) antibody, HIV antibody or syphilis antibody;Clinically apparent disease/infection within 1 month before screening;
* Positive for HBsAg, Hepatitis C virus (HCV) antibody, HIV antibody or syphilis antibody;
* Clinically apparent disease/infection within 1 month before screening;
Oral Device Clinical Trial

The investigators are studying the use of a new medical device developed at Nationwide Children's. This technology has been licensed and produced by Zotarix LLC, a medical device company. It is designed to aid in retraction and provide protection of the lips during surgery. The investigators are not recording any of your identifiable personal health information except for the surgery date. This device, called the LabraGuard is a sterile, soft medical grade silicone, and no alternative device with these exact protective properties exists, and the investigators are trying to learn more about how it performs in different age children.


Eligibility Criteria:
Inclusion Criteria:

* Subjects 21 years of age and under
* Having a surgical procedure done through the mouth where the lips are at risk of injury
* Performed by attendings from either the Otolaryngology department or the Dental department.
* Subject/Subject's guardian provides consent to be in the study

Exclusion Criteria:

* Allergy to silicone
* Unable to achieve good fit
Hypothalamo-pituitary Adrenal Axis Activity and Neuropsychological Consequences in Type 1 Diabetes in Childhood

The general objective is to precise the role of HPA axis activity in neuropsychological consequences of type 1 diabetes. The investigators hypothesize that hyperactivity of HPA axis is associated with higher scores of depression and changes in hippocampal volume and mean diffusion.

* Background: Type 1 diabetes could be associated with hyperactivity of hypothalamo-pituitary adrenal (HPA) axis. Type 1 diabetes is associated with higher frequency neuropsychological consequences as mood disorders and structural changes in brain, particularly in hippocampus.
* Purpose: To describe the association between HPA axis activity and anxiety and depression scores in 6-12 year's old diabetes children.
* Abstract: The general objective is to precise the role of HPA axis activity in neuropsychological consequences of type 1 diabetes. The investigators hypothesize that hyperactivity of HPA axis is associated with higher scores of depression and changes in hippocampal volume and mean diffusion.

Eligibility Criteria:
Inclusion Criteria:

* Diabetic group:

  * diabetes for 1 year
  * 6-12 year's old
  * included in ISIS-DIAB protocol.
* Control group:

  * brother or sister of a diabetic children
  * 6-12 year's old.

Exclusion Criteria:

* Per os or inhaled corticoid in the previous month of inclusion.
* Acute infectious disease in the previous week of inclusion.
* Other chronic disease than diabetes type1.
* Psychiatric disorders or psychiatric treatment.
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis

The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Bronchiectasis (Brx) and if so how it compares to placebo (a substance which does not have any action).


Eligibility Criteria:
Inclusion Criteria:

* Female of non child bearing potential
* Clinical diagnosis of bronchiectasis
* Be sputum producers, with history of chronic expectoration on most days

Exclusion Criteria:

* Concomitant diagnosis of pulmonary disease other than bronchiectasis or COPD
* FEV1 of \<30% of predicted normal
Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease

Study to document pramipexole dosing during monotherapy, occurrence of fluctuations and dyskinesias, dose increases after deterioration of Parkinson's disease (PD) symptoms, assessment of the reasons for add-on treatment with L-Dopa and dosing of pramipexole and L-Dopa when given concomitantly.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of early stage idiopathic Parkinson's Disease
* No pre-treatment with any dopaminergic treatment (de novo patients), or Pre-treatment with L-Dopa at doses of \< 200 mg/d

Exclusion Criteria:

* Treating physicians are asked to consider the regulation described in the Summary of Product Characteristics (SmPC) for the treatment with pramipexole
A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

This study is designed to determine whether patients previously primed with Ad5 of MRKAd5 HIV-1 gag vaccine respond better when boosted with ALVAC-HIV vaccine than when boosted with MKRAd5 HIV-1 gag vaccine.


Eligibility Criteria:
Inclusion Criteria:

* Subject was previously enrolled in Merck HIV Vaccine study V520 Protocol 007 or 012, and received the complete 3-dose regimen during participation
* Subject is in good general health
* Subject is not infected with HIV
* Subject agrees not to donate blood during the first 52 weeks of the study
* Subject agrees not to donate sperm during the first 12 weeks of the study
* Subject who is of reproductive potential agrees to use an acceptable method of birth control through Week 12 of the study

Exclusion Criteria:

* Subject has been administered immune globulin or blood product 3 months prior to receiving study vaccination
* Subject has been vaccinated with a live virus vaccine in the past 30 days
* Subject has been vaccinated with an inactivated vaccine in the past 14 days
* Subject has an active medical disease
* Subject is taking daily required prescription drugs
* Female subject is pregnant, breastfeeding or expecting to conceive
* Subject is positive for HIV
* Subject has used injection drug within the past year
* Subject has a sexual partner that is infected with HIV
* Subject has a sexual partner that is an active injection drug user
* Subject has been treated for or diagnosed with a new sexually transmitted disease in the past 6 months
* Subject engaged in unprotected intercourse with more than 2 persons in the previous 6 months
* Subject engaged in protected intercourse with more than 4 persons in the previous 6 months
* Subject has previously participated in an HIV vaccine clinical trial (other than Merck V520 Protocols 007 and 012)
* Subject weighs less than 110 lbs.
* Subject has a recent history of alcohol abuse
* Subject intends to donate blood in the first 52 weeks of the trial
Non-invasive Peri- and Postoperative Monitoring of Femoral Artery Balloon Angioplasty

This study evaluates a novel noninvasive method to dynamically monitor the effect of percutaneous transluminal angioplasty on arterial pulse wave

Patients with stenosis of superficial femoral artery referred for percutaneous transluminal angioplasty are monitored before, during and after the procedure and pulse wave analysis is conducted.

Eligibility Criteria:
Inclusion Criteria:

1. The patient has been clinically examined at policlinic of vascular surgery
2. The patient has undergone measurement of ankle-brachial index (ABI) and toe-brachial index (TBI) at policlinic of vascular surgery and exhibits abnormal ABI\<0.9 or ABI\>1.3
3. The patient is considered to have an indication for vascular procedure (critical limb ischemia, intermittent claudication)
4. The patient has been examined with magnetic resonance imaging (MRA)
5. The patient has been considered a candidate for superficial femoral artery percutaneous transluminal balloon angioplasty (PTA) and/or stenting

Exclusion Criteria:

1. Pacemaker
2. Measurement disturbs or risks the subject's treatment process

Withdrawal:

1. Emergency cases
2. By subject's denial
3. Inability to detect signals -
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study

This study was a prospective multicenter cohort of severe pneumonia. And by collecting clinical samples to clarify the correlation between lung microbiome, intestinal microbiome, host susceptibility, and prognosis of severe pneumonia patients.

The human lung and intestinal microbiota play an important role in human health. At present, the correlation between lung and intestinal microbiota in severe pneumonia patients and host susceptibility is limited to small sample, single center studies. Due to sample size limitations, the pathogenesis of severe pneumonia caused by many pathogens remains unclear. This study plans to construct sputum, alveolar lavage fluid, feces, and whole blood samples of severe pneumonia patients admitted to the ICU from 2023 to 2025, and collect clinical data from patients to identify changes in lung and intestinal microbiome, host susceptibility, and disease progression risk in different groups of patients.

Eligibility Criteria:
Inclusion Criteria:

1. New lung infection that meets one of the following definitions: the patient receives mechanical ventilation (invasive or non-invasive) due to acute respiratory failure, with a PEEP level of 5cm or above; Patients receiving high flow oxygen therapy with a FiO2 of 50% or more and a PaO2: FiO2 ratio below 300

Exclusion Criteria:

1. Expected length of stay in ICU is less than 1 day
2. Pregnant
Does Wrapping With Bone Marrow Injection Enhance Healing of Meniscal Sutures Into the Avascular Area

This study will compare meniscal healing of non-vascularised area augmented or not by bone marrow injected under a protective collagen membrane (meniscal wrapping)

Historically, meniscus was considered as none essential for knee joint, and its removal by meniscectomy was the first-line treatment. Many studies have shown a negative progress towards osteoarthritis after meniscus ablation. This approach has gradually changed to preserve this meniscal capital, making way for new treatments as sutures. However the vascular organization of the meniscus is crucial for its cure. The healing potential of lesions in the meniscus non-vascularised aera is considered insufficient, and are often treated by a partial meniscectomy, resulting in a high risk of osteoarthritis. It appears therefore necessary to develop new strategies, as meniscal wrapping, to preserve meniscus presenting this type of damage.

Eligibility Criteria:
Inclusion Criteria:

* Symptomatic or traumatic tears of medial or lateral meniscus;
* Tearing affecting: only 2/3 central (= avascular zone) over more than 1 cm OR extending from the peripheral third (= vascularized area) within the avascular zone over more than 1 cm. In this case, preservation of the peripheral third over a width of at least 4 mm from the capsule;
* Single or multiple tears.

Exclusion Criteria:

* Meniscal tears that can not be sutured, reduced / approximated
* Tear creating a meniscal root avulsion
* Partial meniscal tears
* Meniscal tears already sutured
* Cartilage damage in the compartment\> grade 2 (ICRS classification)
* Mechanical axis (varus / valgus) ≥ 2 °
* Untreated ligament deficiency
* Osteotomy and / or concomitant ligament reconstruction, with the exception of ACL reconstruction.
* Compromised general health condition (score ASA score\> 2)
* BMI ≥30
* Active smoking, drug use
* Allergy to porcine collagen
* Poor compliance
A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia

A multi-center, randomized, double-blind, phase III clinical trial to evaluate the efficacy and safety of Olmesartan/Amlodipine/Rosuvastatin combination treatment in patients with concomitant hypertension and hyperlipidemia


Eligibility Criteria:
Inclusion Criteria:

* Age 20 to 80 years
* patients with hypertension and hyperlipidemias

Exclusion Criteria:

* orthostatic hypotension
* History of ventricular tachycardia, atrial fibrillation
* uncontrolled diabetes mellitus
Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer

The main objective of this study is to identify and characterize subpopulations of cells with invasive capacity in colorectal cancer from primary tumor, blood and metastatic samples.

Secondary objectives include:

* Determine the intrinsic properties essential for the dissemination and chemoresistance of these cells capable of initiating tumors
* Identify a "molecular signature" for potential invasiveness and chemoresistance of cells initiating metastases.
* Describe the evolution of patients during 24 months of follow up and correlations with observed cellular profiles.
* Enrich the tumor bank of the institution.

Eligibility Criteria:
Inclusion Criteria:

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* Patient with adenocarcinoma-type colorectal cancer:
* stage III at diagnosis, surgical resection of the primary tumor proposed.
* stage IV at diagnosis, surgical resection of the primary tumor and possibly of metastases proposed.
* Stage IV who have already undergone surgical excision of the primary tumor, and for whom metastasectomy is now proposed.

Exclusion Criteria:

* The patient is participating in another study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* Patients for whom surgical resection of the primary tumor is not considered as an option
* PStage IV at diagnosis, but metastasectomy is not considered as an option
* Patients with positive HIV, Hepatitis B or Hepatitis C serology
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).

This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease). Rimegepant will be further evaluated in this population with as needed use in a 12-week, open-label extension study.

Eligibility Criteria:
Inclusion Criteria:

* Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
* Migraine attacks, on average, lasting about 4 - 72 hours if untreated.
* 4 to 14 migraine days per month on average across the 3 months prior to the Screening Visit (month is defined as 28 days for the purpose of this protocol).
* Less than 15 headache days (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and throughout the Screening Phase.
* Subjects must be able to distinguish migraine attacks from tension/cluster headaches.
* Subjects on prophylactic migraine medication (excluding CGRP antagonists) are permitted to remain on therapy if they have been on a stable dose for at least 3 months (12 weeks) prior to the Screening Visit, and if the dose is not expected to change during the course of the study.
* Triptan unsuitable

Exclusion Criteria:

-Target Disease Exclusion:

1. History of cluster headache, basilar migraine, or hemiplegic migraine
2. Current medication overuse headaches
3. Headaches occurring 15 or more days per month (migraine or non-migraine) in any of the 3 months prior to the Screening Visit
4. Active chronic pain syndrome (such as fibromyalgia, chronic pelvic pain, complex regional pain syndrome \[CRPS\])
5. Other pain syndromes (including trigeminal neuralgia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, interfere with study assessments of safety or efficacy